Ding Zhou

TL;DR: AG-120 (ivosidenib), an inhibitor of the IDH1 mutant enzyme that exhibits profound 2-HG lowering in tumor models and the ability to effect differentiation of primary patient AML samples ex vivo is reported.

TL;DR: Vorasidenib represents a novel dual mIDH1/2 inhibitor that penetrates the brain of several preclinical species and inhibits 2-HG production in glioma tissue by >97% in an orthotopicglioma mouse model.

TL;DR: The spiral ring or bridged ring containing pyrimidine compound can effectively inhibit the growth of various tumor cells, also generates an inhibiting effect on EGFR (epidermal growth factor receptor), and other proteases of Her family, can be used for preparing antitumor drugs, and also can overcome the drug resistance induced by gefitinib, erlotinib and other existing drugs as discussed by the authors.

TL;DR: In this paper, the authors provided a method for administering to a subject in need of a compound described in this paper. Methods of preparing the compounds are also provided, provided that they are therapeutically active compounds and use methods thereof.

TL;DR: In this article, the use of medicaments for treating a cancer characterized by the presence of a mutant allele of IDH1 was discussed, provided are therapeutically active compounds and the use in manufacture of medicament for treating the cancer.